R&D Psychedelic treatments on cusp of approval, but questions re... There is a new wave of psychedelic treatment moving through clinical trials targeting mental health conditions, and they are showing strong efficacy.
Digital Considering current legal risks from the use of AI in the li... The use of artificial intelligence (AI) in the life sciences sector is increasing, and its applications may be transformative.
R&D Integrating pharmaceutical functions: Using quality insights... As the life sciences field becomes more complex, it is apparent that many aspects of product quality and safety processes are inextricably linked
Digital The evolution of computer validation from being on premises ... Regulation and the pharmaceutical sector are intrinsically linked.
Partner Content Partner Content Ensuring A Zero-Risk Data Privacy Environment When Capturing... Capturing Medical Insights With Zero-Risk
Partner Content Partner Content Integrated evidence generation 2.0: A strategy for every sta... The advent of biologic therapies in the 1970s along with the decoding of the human genome in 2003 heralded an explosion in pharmaceutical innovation.
Patients Conference report: Reuters Pharma Europe In this special edition of the pharmaphorum podcast, the tables have turned as Jonah Comstock puts edito
Digital Fixing clinical trial data management It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.